Clinical Study
A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
Table 1
Patient characteristics at baseline.
| | Characteristic | Subjects | | 56 mg/m2 () | 74 mg/m2 () | 98 mg/m2 () |
| | Gender, | | | | | Male | 1 | 4 | 2 | | Female | 2 | 10 | 2 | | Median age (range) | 57 (49–59) | 40.5 (19–68) | 53.5 (42–59) | | ECOG PS, | | | | | 0 | 2 | 9 | 1 | | 1 | 1 | 4 | 3 | | 2 | — | 1 | — | | Type of tumor, | | | | | Non-Hodgkin lymphoma | 1 | 3 | 1 | | Hodgkin lymphoma | — | 5 | — | | Renal carcinoma | 1 | — | — | | Hepatocellular carcinoma | — | 1 | — | | Gallbladder carcinoma | 1 | — | — | | Breast cancer | — | 1 | 1 | | Lung cancer | — | — | 2 | | Other | — | 4 | — | | Prior therapy, | | | | | Surgery | 0 | 7 | 2 | | Radiotherapy | 3 | 7 | 1 | | Chemotherapy | 0 | 2 | 1 | | Other therapy | 0 | 11 | 3 |
|
|
ECOG: Eastern Cooperative Oncology Group; PS: performance status.
|
